entity,start_date,end_date,context,AARSRAPPORT_html,AARSRAPPORT_pdf,AARSRAPPORT_xml,AddressOfAuditorDistrictName,AddressOfAuditorPostCodeIdentifier,AddressOfAuditorStreetBuildingIdentifier,AddressOfAuditorStreetName,AddressOfReportingEntityDistrictName,AddressOfReportingEntityPostCodeIdentifier,AddressOfReportingEntityStreetBuildingIdentifier,AddressOfReportingEntityStreetName,AddressOfSubmittingEnterprisePostcodeAndTown,AddressOfSubmittingEnterpriseStreetAndNumber,AddresseeOfAuditorsReportOnAuditedFinancialStatements,AdjustmentsForCurrentTaxOfPriorPeriod,ClassOfReportingEntity,ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement,ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults,CurrentTaxExpense,DateOfApprovalOfAnnualReport,DateOfFoundationOfReportingEntity,DateOfGeneralMeeting,DescriptionOfAuditor,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfInvestments,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions,DescriptionOfPrimaryActivitiesOfEntity,DescriptionOfQualificationsOfAuditedFinancialStatements,DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod,DisclosureOfAccountingPolicies,DisclosureOfIncomeFromOtherLongtermInvestmentsAndReceivables,GrossResult,IdentificationNumberCvrOfAuditFirm,IdentificationNumberCvrOfReportingEntity,IdentificationNumberCvrOfSubmittingEnterprise,IdentificationOfApprovedAnnualReport,IncomeFromOtherLongtermInvestmentsAndReceivables,IncreaseDecreaseOfEquityThroughChangesInAccountingPolicies,InformationOnReportingClassOfEntity,InformationOnTypeOfSubmittedReport,ManagementsStatementAboutManagementsReview,NameAndSurnameOfAuditor,NameAndSurnameOfChairmanOfGeneralMeeting,NameAndSurnameOfMemberOfExecutiveBoard,NameOfReportingEntity,NameOfSubmittingEnterprise,OtherExternalExpenses,PlaceOfSignatureOfStatement,ProfitLoss,ProfitLossAfterAttributableToMinorityInterest,ProfitLossFromOrdinaryActivitiesBeforeTax,ProfitLossFromOrdinaryOperatingActivities,RecommendationForApprovalOfAnnualReportByGeneralMeeting,RegisteredOfficeOfReportingEntity,ReportingPeriodEndDate,ReportingPeriodStartDate,RestOfOtherFinanceExpenses,SignatureOfAuditorsDate,SignatureOfAuditorsPlace,TaxExpenseOnOrdinaryActivities,TelephoneNumberOfAuditor,TypeOfAuditorAssistance,_id,_index,_score,cvrNummer,indlaesningsId,indlaesningsTidspunkt,offentliggoerelsesTidspunkt,offentliggoerelsestype,omgoerelse,regNummer,regnskabsperiode_slutDato,regnskabsperiode_startDato,sagsNummer,sidstOpdateret,Assets,CashAndCashEquivalents,ContributedCapital,CurrentAssets,CurrentDeferredTaxAssets,Equity,LiabilitiesAndEquity,LiabilitiesOtherThanProvisions,LongtermInvestmentsAndReceivables,NoncurrentAssets,OtherLongtermInvestments,OtherShorttermPayables,RetainedEarnings,SharePremium,ShorttermLiabilitiesOtherThanProvisions,ShorttermReceivables,NameOfAuditFirm
34897808,2015-01-01,2015-12-31,D-2015,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",-41638.0,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",-20800.0,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,735918.0,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,20800.0,Copenhagen,756756.0,756756.0,715118.0,-20800.0,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,-41638.0,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,,,,,,,,,,,,
34897808,2015-01-01,2015-12-31,D-2015-dim-ReserveForEntreprene,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,,,,,,,,,,,,
34897808,2015-01-01,2015-12-31,D-2015-dim-RetainedEarningsMemb,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,756756.0,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,,,,,,,,,,,,
34897808,2015-01-01,2015-12-31,D-2015-dim-RetainedEarningsMemb.1,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,756756.0,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,,,,,,,,,,,,
34897808,2015-12-31,2015-12-31,I-2015-E,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,51525906.0,88605.0,233000.0,133818.0,45213.0,51505105.0,51525906.0,20801.0,51392088.0,51392088.0,51392088.0,20801.0,45835105.0,5437000.0,20801.0,45213.0,
34897808,2015-12-31,2015-12-31,I-2015-E-dim-ContributedCapitalMe,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,233000.0,,,,,,,,,,,
34897808,2015-12-31,2015-12-31,I-2015-E-dim-OtherInvestmentsMemb,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,,,,51392088.0,,,,,,,,
34897808,2015-12-31,2015-12-31,I-2015-E-dim-RetainedEarningsMemb,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,45835105.0,,,,,,,,,,,
34897808,2015-12-31,2015-12-31,I-2015-E-dim-SharePremiumMember,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,5437000.0,,,,,,,,,,,
34897808,2016-01-01,2016-12-31,D-2016,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",-33635.0,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",-22048.0,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,-8287072.0,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,22048.0,Copenhagen,-8273576.0,-8273576.0,-8309215.0,-22048.0,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,-35639.0,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,,,,,,,,,,,,
34897808,2016-01-01,2016-12-31,D-2016-dim-Direktionsmedlem01,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,,,,,,,,,,,,
34897808,2016-01-01,2016-12-31,D-2016-dim-ReserveForEntreprene,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,,,,,,,,,,,,
34897808,2016-01-01,2016-12-31,D-2016-dim-RetainedEarningsMemb,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,-8273576.0,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,,,,,,,,,,,,
34897808,2016-01-01,2016-12-31,D-2016-dim-RetainedEarningsMemb.1,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,-8273576.0,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,,,,,,,,,,,,
34897808,2016-01-01,2016-12-31,D-2016-dim-Revisionsvirksomhed0,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,,,,,,,,,,,,Deloitte Statsautoriseret Revisionspartnerselskab
34897808,2016-01-01,2016-12-31,D-2016-dim-Revisionsvirksomhed0.1,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,,,,,,,,,,,,
34897808,2016-01-01,2016-12-31,D-2016-dim-Revisionsvirksomhed0.2,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,,,,,,,,,,,,
34897808,2016-12-31,2016-12-31,I-2016-E,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,43249829.0,20133.0,233000.0,98981.0,78848.0,43231529.0,43249829.0,18300.0,43150848.0,43150848.0,43150848.0,18300.0,37561529.0,5437000.0,18300.0,78848.0,
34897808,2016-12-31,2016-12-31,I-2016-E-dim-ContributedCapitalMe,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,233000.0,,,,,,,,,,,
34897808,2016-12-31,2016-12-31,I-2016-E-dim-OtherInvestmentsMemb,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,,,,43150848.0,,,,,,,,
34897808,2016-12-31,2016-12-31,I-2016-E-dim-RetainedEarningsMemb,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,37561529.0,,,,,,,,,,,
34897808,2016-12-31,2016-12-31,I-2016-E-dim-SharePremiumMember,,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzkxL2Q3LzI3L2Y1LzM0ZGUtNGE1My05OTJhLWNjMWRiY2Q0YTA2MQ.pdf,http://regnskaber.virk.dk/80879843/ZG9rdW1lbnRsYWdlcjovLzAzLzFjLzY1LzhhL2EwLzRhZWYtNDE4Yy05M2JkLTRhYTFlMjBhZDUxOQ.xml,KÃ¸benhavn C,900.0,6.0,WeidekampsgadePostboks 1600,Copenhagen,1100.0,"24 A, 1.",Ãstergade,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of NB FP Investment SLP ApS,-2004.0,Regnskabsklasse B,The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2016 and of the results of its operations for the financial year 01.01.2016 - 31.12.2016.",,2017-02-20,2013-01-03,2017-03-13,State Authorised Public Accountant,Cash comprises cash in bank deposits.,Other external expenses include expenses relating to the Entityâs ordinary activities.,Income from other fixed asset investments comprises fair value adjustments of investments in portfolio companies for the financial year. Other financial expenses comprise interest expenses and bank fees.,Other investments comprise investments in portfolio companies which are measured at fair value at the balance sheet date in accordance with the Danish Financial Statements Act Â§ 37. Value adjustments are recognized in the income statement.,"Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.",NB FP Investment SLP ApS is an investment company focusing on early stage investments in the biotech industry. The investments are made through investment funds.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs responsibilities for the audit of the financial statements section of this auditorâs report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.","On January 17th Forward Pharma A/S announced a settlement agreement with Biogen that included payment of 1,25 bn USD and the possibility for royalties on Tecfidera product. For more information please visit http://forward-pharma.com",The accounting policies applied to these financial statements are consistent with those applied last year.,"The fair value adjustment is comprised of NB FP Investment SLP ApSâs share in the investment funds NB FP Investment K/S and NB FP Investment II K/S. The two investment funds have invested in Forward Pharma A/S, which is listed on Nasdaq and the fair value is measured at the share price.",,33963556.0,34897808.0,33963556.0,The Executive Board have today considered and approved the annual report of NB FP Investment SLP ApS for the financial year 01.01.2016 - 31.12.2016.,,0.0,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises.,Ãrsrapport,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Bill Haudal Pedersen,Jakob Mosegaard Larsen,Florian SchÃ¶nharting,NB FP Investment SLP ApS,Deloitte Statsautoriseret Revisionspartnerselskab,,Copenhagen,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2016-12-31,2016-01-01,95.0,2017-02-20,Copenhagen,,36 10 20 30,RevisionspÃ¥tegning,urn:ofk:oid:23596670,indberetninger-20180424,2.5095785,34897808,,2018-03-28T00:15:03.428Z,2017-03-14T17:55:04.383Z,regnskab,0.0,,2016-12-31,2016-01-01,X17-AE-40-BX,2017-03-14T17:55:04.546Z,,,,,,5437000.0,,,,,,,,,,,
